Global radiopharmaceutical company Cyclopharm (ASX:CYC) has entered into a standard commercial partnership with Yale following Technegas’ approval by the U.S. FDA | https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02766065-2A1501471
EDE
0.003
200%
OEL
0.005
-58.3%
LOC
0.115
82.5%
AOK
0.002
-33.3%
DTR
0.097
76.4%
OSL
0.002
-33.3%
CVR
0.28
69.7%
RDS
0.005
-28.6%
LKY
0.08
63.3%
ADG
0.006
-25%
HIO
0.026
62.5%
ALM
0.003
-25%
RPG
0.038
58.3%
JLL
0.37
-24.5%
G50
0.19
52%
AW1
0.039
-23.5%
ASR
0.003
50%
FCT
0.013
-23.5%
AYM
0.003
50%
POD
0.029
-21.6%
CTN
0.003
50%
CML
0.13
-21.2%
JAV
0.003
50%
AQX
0.004
-20%
YAR
0.009
50%
BEZ
0.032
-20%
BTM
0.125
42%
KPO
0.004
-20%
TM1
0.039
39.3%
TEE
0.052
-20%
ERD
1.39
39%
WMG
0.17
-19%
OIL
0.15
36.4%
DTZ
0.048
-18.6%
EDU
0.27
35%
MGA
0.066
-18.5%
AKN
0.008
33.3%
AON
0.009
-18.2%
RNT
0.032
33.3%
VEN
0.005
-16.7%
